January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan.

Renowned British dancer hosts one-week intensive dance workshop

The school of Performing Arts is once again hosting a workshop facilitated by renowned British dancer Shevelle Dynott, who has appeared in numerous productions for the English National Ballet, including Alice in Wonderland as the Mock Turtle, Puss in B…